ABOG Gynecologic Oncology common mistakes
ABOG Gynecologic Oncology · Understand the traps and how to avoid them.
For a 28-year-old with an ASC-US Pap and positive high-risk HPV, they select 'immediate excisional cone biopsy' or 'hysterectomy' as the next step instead of colposcopy with directed biopsy.
They collapse screening and diagnosis into one step; the fear of missing cancer creates an urgency that compresses the mandated two-step pathway, and they forget that treatment is directed by histology, not by cytology.
What to do instead
For every abnormal screen, recite the sequence: abnormal screen → colposcopy with directed biopsy → only when CIN2+ or an unsatisfactory colposcopy with discordance is documented does an excisional procedure become treatment rather than diagnosis. Practice saying aloud that hysterectomy is never a diagnostic step for cervical dysplasia and that it only appears on a management line after a tissue diagnosis of AIS or cancer is established.
They continue annual cytology/HPV co-testing in a patient who had a total hysterectomy for benign indications, or they start screening a 19-year-old who has been sexually active, or they stop screening at 65 in a patient with a recent abnormal result.
Guideline age and exit criteria are memorized as vaguely associated numbers ('65', 'three negatives') without the qualifying conditions attached to them, so the candidate pattern-matches the number and ignores the prerequisites.
What to do instead
Build a one-line decision rule for each screening question: start at 21 regardless of sexual history; exit at 65 only after adequate prior negative screening with no abnormal result in the preceding interval; stop after hysterectomy only if the cervix was removed for benign disease with no prior CIN2+. State the qualifying condition in the answer choice, because the option that omits it is usually the distractor.
For an adnexal mass that appears confined to the ovary, they choose 'total abdominal hysterectomy with bilateral salpingo-oophorectomy' and stop there, without omentectomy, peritoneal biopsies, pelvic and para-aortic lymphadenectomy, or cytology.
They focus on the visible lesion and the therapeutic intent and treat staging as an academic footnote, forgetting that the stage-not the size of the operation-determines whether adjuvant chemotherapy is given.
What to do instead
Memorize the staging procedure as a fixed checklist per site and rehearse it as a list before answering: washings, omentectomy, systematic peritoneal biopsies, hysterectomy/BSO, and pelvic plus para-aortic lymph node dissection for apparent early-stage ovarian cancer. If a proposed operation on the exam omits a checklist item in an apparent early-stage patient, mark it as incomplete staging unless the stem gives a specific reason (e.g., mucinous histology limits the value of routine nodal dissection).
For a patient with bulky carcinomatosis and newly diagnosed ovarian cancer they default to primary debulking whenever the stem says 'good performance status,' without proposing assessment of resectability or discussing neoadjuvant chemotherapy plus interval debulking as an equally valid strategy.
Recall of 'maximum cytoreduction improves survival' is not balanced by recall of the randomized trial showing non-inferior survival with neoadjuvant chemotherapy and less perioperative morbidity when complete resection is not achievable.
What to do instead
Attach a threshold to the answer: primary cytoreduction is the option only when the surgeon can credibly plan to leave no gross residual disease; when stranding, port-site or diaphragmatic disease, or upper abdominal involvement makes complete resection unlikely, neoadjuvant platinum-based chemotherapy followed by interval debulking is the preferred answer. On the exam, look for the phrase about residual disease in the options and let it override enthusiasm about upfront surgery.
They label a recurrence 'platinum-resistant' because it appeared 5 months after the last cycle, or 'platinum-sensitive' regardless of the interval, and then choose a non-platinum or platinum-containing regimen to match the wrong label.
They anchor on the word 'recurrence' rather than measuring the platinum-free interval, and they don't realize the interval is defined from the last dose of platinum to the date progression is documented.
What to do instead
Before selecting the regimen, write the interval on scratch paper: from the last platinum dose to documented progression. More than 6 months means platinum-sensitive, so a platinum doublet is appropriate; 6 months or less means platinum-resistant, so single-agent non-platinum therapy or clinical trial is appropriate. When the stem gives dates rather than a label, always do that subtraction explicitly.
They prescribe a full-dose platinum doublet in a patient with a creatinine clearance in the 30s, pre-existing grade 2 peripheral neuropathy, or an ejection fraction of 40%, without dose modification or an alternative agent.
Options are selected by diagnosis rather than by the patient, so the reason the stem gave organ function and comorbidity details is ignored; the examination deliberately plants these details next to the correct answer and also puts them in the answer option.
What to do instead
Treat every comorbidity in the stem as a decision point, and modulate the choice of regimen to it: carboplatin with an AUC-based dose rather than cisplatin when renal function is impaired, an alternative to a taxane when neuropathy is already present, and avoidance of anthracycline when cardiac reserve is poor. Before committing to an option, check that each comorbidity in the stem is either addressed by your choice or does not conflict with it.
For definitive treatment of a stage IB3 to IIIC1 cervical cancer, they choose external beam radiation with concurrent cisplatin and stop, omitting the brachytherapy boost; or they treat a para-aortic-positive patient with the same pelvic field as a node-negative patient.
Chemoradiation is recalled as one package, and the brachytherapy component-the part that delivers curative central dose-does not come to mind; similarly, the extended-field concept is recognized in theory but not applied to the field design.
What to do instead
Rehearse definitive cervical radiation as three components: external beam, concurrent weekly cisplatin, and image-guided brachytherapy. A treatment plan that omits any one of the three is incorrect. Separately memorize that para-aortic nodal involvement extends the field to the para-aortic chain up to the renal vessels, with the prescription and normal-tissue constraints modified accordingly.
They interpret any p53 immunostaining abnormality as proof of serous carcinoma, or call p16 block positivity in the lower uterine segment an HPV-driven cervical primary, or omit universal mismatch repair testing in a new endometrial cancer.
They treat a single stain as a diagnosis instead of as a pattern with a differential diagnosis, and because the stains are memorized as 'serous = p53 abnormal' and 'p16 = HPV,' the caveats drop away.
What to do instead
Anchor each stain to its pattern and its limits: p53 abnormal means a mutation-type pattern that also occurs in a substantial fraction of high-grade endometrioid carcinomas, so grade and morphology decide; p16 block positivity is expected in normal lower uterine segment and is not by itself evidence of HPV. Make a habit of stating that all endometrial carcinomas get mismatch repair or MSI testing for Lynch syndrome at diagnosis. If a stem's histology does not fit the stain, say so rather than following the stain.
After reading a randomized non-inferiority trial, they conclude the new regimen is 'as good as' or 'better than' standard therapy without checking the margin or the confidence interval, or they accept progression-free survival as proof of a survival benefit.
The abstract conclusion sentence is read as if it were a superiority trial, and the margin, the upper confidence bound, and the distinction between a surrogate endpoint and overall survival are not part of their reading habit.
What to do instead
For any non-inferiority result, ask three questions before answering: What was the prespecified margin? Does the confidence interval lie entirely within it? Is a per-protocol or intention-to-treat analysis being reported, and why? Separately, when the endpoint is progression-free survival, state explicitly that a benefit in that endpoint does not establish overall survival benefit unless the trial shows it, then choose the option that reflects that limitation.
They treat a consultation about palliative care as equivalent to enrollment in hospice, defer the discussion until all chemotherapy options are exhausted, or fail to manage a malignant bowel obstruction with octreotide and dexamethasone while pursuing further cytotoxics.
Palliative care and end-of-life care are fused into one concept, so raising the topic feels like abandoning the patient-a discomfort that gets in the way of recalling that early palliative care improves quality of life and can prolong survival.
What to do instead
Separate the two terms explicitly when studying: palliative care is symptom management alongside disease-directed therapy and is appropriate at diagnosis of advanced disease; hospice is a benefit defined by prognosis and goals. Practice responses that recommend early integrated palliative care referral for any patient with advanced gynecologic cancer and high symptom burden. For bowel obstruction, memorize the medical armamentarium-octreotide to reduce secretions, dexamethasone, and antiemetics-before considering surgical or stent options.